BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

VolverVolver

Resultados 95 resultados LastUpdate Última actualización 28/11/2022 [13:59:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Página1 de 4 nextPage   por página


METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2022372544A1 24/11/2022

Solicitante:

MEHARRY MEDICAL COLLEGE [US]

US_2020149087_A1

Resumen de: US2022372544A1

Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

traducir

ANTI-TREM-1 ANTIBODIES AND USES THEREOF

NºPublicación: US2022372139A1 24/11/2022

Solicitante:

BRISTOL MYERS SQUIBB COMPANY [US]

JP_2022540674_A

Resumen de: US2022372139A1

Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene. Also disclosed herein are methods of determining efficacy of an anti-TREM-1 antibody comprising measuring an expression level of a TREM-1 associated gene. Methods of identifying non-responder to a standard of care treatment and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody are also disclosed.

traducir

PREDICTION OF CLINICAL RESPONSE TO IL23-ANTAGONISTS USING IL23 PATHWAY BIOMARKERS

NºPublicación: US2022373539A1 24/11/2022

Solicitante:

AMGEN INC [US]
MEDIMMUNE LLC [US]

Resumen de: US2022373539A1

The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an anti-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

traducir

PREDICTING A TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE

NºPublicación: US2022364171A1 17/11/2022

Solicitante:

UNIV LEUVEN KATH [BE]

WO_2020104705_A2

Resumen de: US2022364171A1

In general the present invention concerns a method for predicting the therapeutic outcome of a treatment of in inflammatory bowel disease for anti-TNF agents, anti-α4β7-integrin agents and/or anti-IL-12/23 agents. The method defines which the agents are likely to provide the best healing effect for a particular patients affected by an inflammatory bowel disease. In particular the method predicts the therapeutic outcome of a treatment of anti-TNF agents in inflammatory bowel disease.

traducir

SIGNATURE OF TL1A (TNFSF15) SIGNALING PATHWAY

NºPublicación: US2022363745A1 17/11/2022

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2020216526_A1

Resumen de: US2022363745A1

The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.

traducir

METHOD OF USING GENETIC MARKERS, SINGLE NUCLEOTIDE POLYMORPHISMS AND/OR INDELS TO DETERMINE RESPONSIVENESS TO IL-10 OR IL-10 DERIVATIVE TREATMENT

NºPublicación: EP4087947A1 16/11/2022

Solicitante:

DEKA BIOSCIENCES INC [US]

CN_115298328_A

Resumen de: US2021214782A1

The application relates to the discovery of novel gene expression profiles and/or single nucleotide polymorphisms (SNP) and/or insertions or deletions of bases (INDEL) profiles that correlate with a subject's positive receptiveness to Interleukin 10 (IL-10) or IL-10 based agent treatments. The application also relates to methods of treating patients with an IL-10 or IL-10 based agent treatment by screening, examining, or determine patients possessing a gene expression profile and/or SNP and/or INDEL profile most receptive to the treatment.

traducir

DOSAGE REGIMEN FOR MADCAM ANTAGONISTS

NºPublicación: ES2927958T3 14/11/2022

Solicitante:

PFIZER INC

CN_114732899_A

Resumen de: WO2016110806A2

The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.

traducir

BIOMARKERS FOR IRRITABLE BOWEL SYNDROME

NºPublicación: US2022357333A1 10/11/2022

Solicitante:

UNIV LIVERPOOL [GB]
KING S COLLEGE LONDON [GB]

CN_114174828_A

Resumen de: US2022357333A1

The present invention relates to a method of determining the probability that an individual has irritable bowel syndrome and whether the individual will respond to dietary intervention. The present invention also provides a method of determining the probability that an individual with irritable bowel syndrome will respond to dietary intervention. There is also provided the use of a compound as defined herein as a biomarker.

traducir

USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS

NºPublicación: US2022357343A1 10/11/2022

Solicitante:

GENENTECH INC [US]

JP_2022106732_A

Resumen de: US2022357343A1

Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator (“biomarker”) of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of assessing the effect, efficacy, or responsiveness to beta7 integrin antagonist treatment by measuring gene expression levels of one or more integrin receptor ligands, lymphocyte genes, cytokine genes, or the number of alphaE-positive cells in intestinal crypt epithelium are provided.

traducir

TEST AND IN VITRO DIAGNOSIS OF IRRITABLE BOWEL SYNDROME

NºPublicación: EP4085256A1 09/11/2022

Solicitante:

IMMUNDIAGNOSTIK AG [DE]

WO_2021151942_A1

Resumen de: WO2021151942A1

In vitro method for determining the type and severity of a gastrointestinal disorder in a subject suspected of suffering irritable bowel syndrome (IBS), comprising the steps of a) performing an assay method for detecting the presence of γ-tryptase in a fecal sample obtained from said patient; b) measuring the concentration of γ-tryptase in said fecal sample; c) comparing said measured concentration of γ-tryptase to a first predetermined reference value; and d) assessing of said patient by assigning an increased likelihood of suffering irritable bowel syndrome (IBS) when said measured concentration of γ-tryptase is higher than said predetermined reference value, or by assigning a decreased likelihood of suffering irritable bowel syndrome (IBS) when said measured concentration of γ-tryptase is lower than said predetermined reference value.

traducir

METHOD OF USING GENETIC MARKERS, SINGLE NUCLEOTIDE POLYMORPHISMS AND/OR INDELS TO DETERMINE RESPONSIVENESS TO IL-10 OR IL-10 DERIVATIVE TREATMENT

NºPublicación: CN115298328A 04/11/2022

Solicitante:

德卡生物科学公司

CA_3164376_A1

Resumen de: US2021214782A1

The application relates to the discovery of novel gene expression profiles and/or single nucleotide polymorphisms (SNP) and/or insertions or deletions of bases (INDEL) profiles that correlate with a subject's positive receptiveness to Interleukin 10 (IL-10) or IL-10 based agent treatments. The application also relates to methods of treating patients with an IL-10 or IL-10 based agent treatment by screening, examining, or determine patients possessing a gene expression profile and/or SNP and/or INDEL profile most receptive to the treatment.

traducir

PATIENT SELECTION METHODS AND KITS FOR THERAPIES TARGETING TL1A

NºPublicación: WO2022232253A1 03/11/2022

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

Resumen de: WO2022232253A1

A Provided herein are methods and compositions for patient selection and therapies targeting TL1A. In particular, provided is a method of treating moderate to severely active Crohn's disease (CD) or ulcerative colitis (UC) in a subject, the method comprising: administering a therapeutically effective amount of an inhibitor of Tumor necrosis factor-like cytokine 1A (TL1A) activity or expression to a subject with moderately to severely active CD or UC that has been determined have a polygenetic risk score (PRS) in the 75th percentile, which is indicative of high fold-change of TL1A expression relative to a cut-off fold-change value. Calculating a PRS comprises providing genomic data comprising one or more genotypes (e.g. rs11221332, rs7134599, rs6062496, rs4246905, rs7468800, rs1569328, rs2284553, rs6062504, and rs7556897) of the subject associated with high TL1A fold-change relative to an index or a control.

traducir

USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS

NºPublicación: US2022349903A1 03/11/2022

Solicitante:

GENENTECH INC [US]

US_2019310266_A1

Resumen de: US2022349903A1

The present invention is directed to methods of using biomarkers to assess treatment of gastrointestinal inflammatory disorders with beta7 antagonists. More particularly, the present invention relates to methods of using the level of gut-homing lymphocytes in peripheral blood, the level of drug occupancy on gut-homing lymphocytes, and/or the level of beta7 integrin receptors on gut-homing lymphocytes as indicators (or biomarkers) of the effect, efficacy, safety, prognosis, and/or dosing of therapeutic agents, such as beta7 integrin antagonists, for the treatment of gastrointestinal inflammatory disorders.

traducir

APPARATUSES AND SYSTEMS FOR TRACKING BOWEL MOVEMENT AND URINATION AND METHODS OF USING SAME

NºPublicación: US2022346720A1 03/11/2022

Solicitante:

UNIV DUKE [US]

WO_2021055681_A1

Resumen de: US2022346720A1

The present disclosure provides devices, systems, and methods for the prognosis and management of diseases and conditions. In particular, the present disclosure provides devices, systems, and methods directed to a toilet apparatus for the automatic tracking of a subject's urination and bowel movements to enhance the diagnosis and treatment of various diseases and conditions.

traducir

SYSTEMS AND DEVICES FOR DETECTING BIOMARKERS IN SITU AND RELATED METHODS

NºPublicación: WO2022232188A1 03/11/2022

Solicitante:

MASSACHUSETTS INST TECHNOLOGY [US]
UNIV BOSTON [US]
BRIGHAM & WOMENS HOSPITAL INC [US]

Resumen de: WO2022232188A1

Transient molecules in the gastrointestinal (GI) tract, such as nitric oxide and hydrogen sulfide, are important signals and mediators of inflammatory bowel disease (IBD). Because these molecules may be short-lived in the body, they are difficult to detect. To track these reactive molecules in the GI tract, a miniaturized device has been developed that integrates genetically engineered probiotic biosensors with a custom- designed photodetector and readout chip. Leveraging the molecular specificity of living sensors, bacteria were genetically encoded to respond to IBD-associated molecules by luminescing. Low-power electronic readout circuits (e.g., using nanowatt power) integrated into the device convert the light from just 1 p L of bacterial culture into a wireless signal. Biosensor monitoring was demonstrated in the GI tract of small and large animal models and integration of all components into a sub- 1.4 cm3 ingestible form factor capable of supporting wireless communication. The wireless detection of short-lived, disease-associated molecules may support earlier diagnosis of disease than is currently possible, more accurate tracking of disease progression, and more timely communication between patient and their care team supporting remote personalized care.

traducir

COMPOSITIONS, DEVICES, AND METHODS OF IBS SENSITIVITY TESTING

NºPublicación: CN115248311A 28/10/2022

Solicitante:

拜尔梅里科有限公司

KR_20220038183_PA

Resumen de: US2017322223A1

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≦0.07 as determined by their raw p-value or an average discriminatory p-value of ≦0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

traducir

BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE ESCHERICHIA COLI

NºPublicación: WO2022224193A1 27/10/2022

Solicitante:

FERRING BV [NL]

Resumen de: WO2022224193A1

Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.

traducir

METHOD AND KIT FOR BOWEL PREPARATION

NºPublicación: US2022339242A1 27/10/2022

Solicitante:

MSM INNOVATIONS INC [US]

US_2019314450_A1

Resumen de: US2022339242A1

The present invention provides methods and taste-modifying kits for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods and taste-modifying kits can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.

traducir

USE OF BRAZIKUMAB TO TREAT CROHN'S DISEASE

NºPublicación: JP2022544992A 24/10/2022

Solicitante:

アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニー

CN_114641493_A

Resumen de: WO2021035129A1

The disclosure relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23, but do not inhibit IL-12. The disclosure also relates to methods of selecting a subject amenable to IL-23 inhibition therapy to treat Crohn's disease as well as methods of identifying a patient sub-population amenable to such treatment.

traducir

Biomarker of fibrosis

NºPublicación: AU2021257616A1 20/10/2022

Solicitante:

NORDIC BIOSCIENCE AS

WO_2021209540_A1

Resumen de: AU2021257616A1

The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.

traducir

FOOD INGREDIENTS PRODUCED FROM HIGH AMYLOSE WHEAT

NºPublicación: US2022330585A1 20/10/2022

Solicitante:

ARISTA CEREAL TECH PTY LIMITED [AU]

US_2020345045_A1

Resumen de: US2022330585A1

Provided are food and drink ingredients produced from wheat grain which has a low level (2-30%) of total starch branching enzyme II activity and an amylose content in the starch of at least 50% (w/w), and processes for producing and using the ingredients. Also provided are foods produced from the ingredients which may be used in humans to improve one or more parameters of metabolic health, bowel health or cardiovascular health.

traducir

MACROPHAGE STIMULATING 1 RECEPTOR (MST1R) VARIANTS AND USES THEREOF

NºPublicación: JP2022544393A 18/10/2022

Solicitante:

リジェネロン・ファーマシューティカルズ・インコーポレイテッド

AU_2020329191_A1

Resumen de: WO2021030358A1

Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein.

traducir

Anti-human p40 protein domain antibody and application thereof

NºPublicación: JP2022544050A 17/10/2022

Solicitante:

アケソ・バイオファーマ・インコーポレイテッド

US_2022298235_A1

Resumen de: CN112079922A

The present invention relates to antibodies for treating or preventing autoimmune diseases. The antibody comprises a heavy chain variable region as shown shown in SEQ ID NO: 1 or SEQ ID NO: 24 and a light chain variable region as shown in SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 25.

traducir

METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS

NºPublicación: US2022323406A1 13/10/2022

Solicitante:

MASSACHUSETTS INST TECHNOLOGY [US]
BRIGHAM & WOMENS HOSPITAL INC [US]

WO_2020247836_A1

Resumen de: US2022323406A1

The subject matter disclosed herein is generally directed to modulation of genes and pathways that drive differentiation of LGR5+ stem cells. The methods and compositions can be used to treat diseases associated with aberrant epithelial barrier function.

traducir

Composition for Prophylaxis and Treatment of Ulcerative Colitis

Nº publicación: AU2021201899A1 13/10/2022

Solicitante:

SEOWON UNIV INSTITUTE OF INDUSTRY ACADEMY COLLABORATION [KR]

Resumen de: AU2021201899A1

The present invention relates to a composition useful for preventing and treating ulcerative colitis or alleviating the symptoms of ulcerative colitis that can be safely taken without side effects and show excellent efficacy against sulfasalazine, a standard treatment. More specifically, the present invention is directed to a pharmaceutical composition for prophylaxis and treatment of ulcerative colitis that contains a radish extract as an effective ingredient.

traducir

Página1 de 4 nextPage por página

punteroimgVolver